Media stories about BeiGene (NASDAQ:BGNE) have been trending somewhat positive on Monday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BeiGene earned a coverage optimism score of 0.21 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.0981363100973 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
BGNE has been the topic of a number of recent analyst reports. Ladenburg Thalmann Financial Services assumed coverage on shares of BeiGene in a research note on Monday, August 7th. They set a “buy” rating and a $81.00 price target on the stock. Maxim Group reissued a “buy” rating and issued a $77.00 target price on shares of BeiGene in a research note on Monday, September 11th. Zacks Investment Research raised shares of BeiGene from a “hold” rating to a “buy” rating and set a $115.00 target price on the stock in a research note on Tuesday, October 3rd. Morgan Stanley reaffirmed an “overweight” rating and set a $95.00 price target (up from $87.00) on shares of BeiGene in a report on Friday, October 6th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $86.00 price target (up from $43.00) on shares of BeiGene in a report on Tuesday, August 15th. Seven equities research analysts have rated the stock with a buy rating, BeiGene has a consensus rating of “Buy” and an average target price of $92.50.
BeiGene (NASDAQ BGNE) opened at $84.22 on Monday. BeiGene has a fifty-two week low of $26.43 and a fifty-two week high of $118.95. The company has a debt-to-equity ratio of 0.57, a quick ratio of 8.38 and a current ratio of 8.38.
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Receive News & Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.